Eli Lilly and Company (BCBA:LLY)
Argentina
· Delayed Price · Currency is ARS | Market Cap | 1,326.06T |
| Revenue (ttm) | 94.60T |
| Net Income (ttm) | 29.96T |
| Shares Out | n/a |
| EPS (ttm) | 33,309.63 |
| PE Ratio | 44.27 |
| Forward PE | 30.36 |
| Dividend | 108.17 (0.40%) |
| Ex-Dividend Date | Feb 13, 2026 |
| Volume | 5,052 |
| Average Volume | 9,311 |
| Open | 26,820 |
| Previous Close | 26,900 |
| Day's Range | 26,820 - 27,460 |
| 52-Week Range | 14,500 - 31,100 |
| Beta | 0.39 |
| RSI | 48.05 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USDNews
Why Eli Lilly is Winning the Weight Loss War
WSJ's David Wainer breaks down why Novo Nordisk struggled and Eli Lilly prospered in the weight loss drug market. #
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
The positive opinion is based on data from the Phase 3 BRAVE-AA-PEDS study, in which 42% of patients with severe alopecia areata (AA) reached 80% or more scalp hair coverage at 36 weeks The study is t...
Eli Lilly reports additional data on weight-loss pill from diabetes trial
Eli Lilly on Thursday released new data from a head-to-head trial of its experimental weight-loss pill, orforglipron, and rival Novo Nordisk's oral semaglutide in diabetes patients, giving a more deta...
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet
For the primary endpoint, orforglipron 36 mg lowered A1C by 2.2% vs. 1.4% with oral semaglutide 14 mg in ACHIEVE-3 In a key secondary endpoint, participants on orforglipron 36 mg lost 19.7 lbs (9.2%) ...
Columbia Balanced Fund Q4 2025 Contributors And Detractors
Lilly delivered exceptional performance over the period, driven by sustained strength in its diabetes and obesity portfolio. Applied Materials outperformed during the quarter, as AI-driven wafer-fab i...
Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan
Shares of Novo Nordisk and rival Eli Lilly fell on Tuesday after a report said price cuts are coming for the popular weight-loss drugs.
Novo's stumbles burnish Lilly's widening lead in weight-loss drugs
With U.S. arch rival Eli Lilly streaking away on weight-loss prescriptions and valuation, the last thing Novo Nordisk needed was to give it a helping hand. Then came the latest trial data for the Dani...
Eli Lilly's Zepbound Gets FDA OK for Multi-Dose Pen
The company said the weight-loss drug will be available at the same self-pay price in either the single-dose vial format or the multi-dose pen that delivers four weekly injections from a single device...
Novo Nordisk's Loss Is Eli Lilly's Gain
Novo Nordisk's stock hit a 52-week low after its REDEFINE 4 trial failed to demonstrate non-inferiority in weight loss compared to Eli Lilly's tirzepatide, marketed under the Zepbound and Mounjaro bra...
Eli Lilly bets on multi-dose Zepbound pen in GLP-1 retention push
Millions of people on GLP-1 weight-loss drugs know the weekly routine by heart: a new injector pen, a new box, another reminder to refill, and one more item for the sharps bin. Eli Lilly is trying to ...
Eli Lilly launches new form of obesity drug Zepbound with a month's worth of doses in one pen
Eli Lilly on Monday launched a new form of its blockbuster obesity drug, Zepbound, that offers a month's worth of doses in a single pen. The pen could serve as a more convenient option for some patien...
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPen
Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound® Zepbound patients can access all doses in either multi-dose KwikPen...
Novo Nordisk Stock Plunges and Eli Lilly Jumps. It's All Down to This Weight-Loss Drug Trial.
Novo shares slump after the Danish drugmaker's experimental obesity drug fails to beat Lilly's treatment in an 84-week trial.
These Stocks Are Today's Movers: Novo Nordisk, Eli Lilly, Paramount, Nvidia, and More
Nvidia shares tick up as investors await the chip maker's fourth-quarter earnings, which likely will reveal how artificial-intelligence demand is holding up.
Novo Nordisk pitted a new weight-loss drug against Eli Lilly — and lost
Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn't cut as much weight as an Eli Lilly product.
Novo Nordisk's obesity drug falls short against Eli Lilly's in Copenhagen trial
Novo Nordisk said on Monday its experimental obesity drug CagriSema did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly's Tirzepatide in reducing ...
Our Top 10 High Growth Dividend Stocks - February 2026
The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rat...
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)
Landmark VIVID-2 data showed more than 90% of patients who achieved steroid-free remission at one year maintained steroid-free control through three years Additional new data revealed exceptionally l...
CSL signs licensing deal with Eli Lilly for clazakizumab to treat kidney disease
Australia's CSL said on Wednesday it had entered into an exclusive licensing agreement with Eli Lilly and Co , granting it certain rights to develop and commercialise clazakizumab, an antibody aimed a...
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and Company
ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics achieves second success milestone for in vivo program in collaboration with Eli Lilly and Company.
Lilly targets India as global export hub amid booming Mounjaro sales, executive says
Mounjaro-maker Eli Lilly wants to turn India into a hub for its global supply chain, a senior executive at the U.S. drugmaker said, as part of its previously committed $1 billion investment to contrac...
Impax U.S. Sustainable Economy Fund Q4 2025 Contributors And Detractors
Eli Lilly is included due to its strategic positioning with respect to sustainability opportunities, specifically in HealthCare Access and Innovation. Advanced Micro Devices is owned for its exception...
Lilly to participate in TD Cowen's 46th Annual Health Care Conference
INDIANAPOLIS, Feb. 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in TD Cowen's 46th Annual Health Care Conference on March 2, 2026. Lucas Montarce, executive vice presiden...
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancer
Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on pr...